Mabwell (Shanghai) Bioscience Co., Ltd.
Mabwell (Shanghai) Bioscience Co., Ltd., a leading biopharmaceutical company based in China, is renowned for its innovative contributions to the biotechnology sector. Founded in 2016, Mabwell has rapidly established itself as a key player in the development of monoclonal antibodies and other biologics, focusing on therapeutic solutions for oncology and autoimmune diseases. Headquartered in Shanghai, Mabwell operates extensively across major regions in China and is expanding its global footprint. The company’s core offerings include cutting-edge antibody drugs and advanced drug delivery systems, distinguished by their high specificity and efficacy. Mabwell's commitment to research and development has led to significant milestones, including successful collaborations and partnerships that enhance its market position. With a strong emphasis on quality and innovation, Mabwell continues to drive advancements in the biopharmaceutical industry.
DitchCarbon Score
How does Mabwell (Shanghai) Bioscience Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mabwell (Shanghai) Bioscience Co., Ltd.'s score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mabwell (Shanghai) Bioscience Co., Ltd.'s reported carbon emissions
Mabwell (Shanghai) Bioscience Co., Ltd., headquartered in China, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Mabwell may not have established formal commitments to reduce carbon emissions or may not publicly disclose such information. As the biopharmaceutical industry increasingly prioritises sustainability, companies like Mabwell are encouraged to adopt transparent climate strategies and set measurable targets to align with global climate goals. Without specific emissions data or reduction initiatives, it remains unclear how Mabwell is addressing its environmental impact within the broader context of industry standards and expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mabwell (Shanghai) Bioscience Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
